A股異動 | 經緯輝開(300120.SZ)五連板 擬對諾思(天津)微系統進行投資
格隆匯7月24日丨經緯輝開(300120.SZ)本週連續5日漲停,封單近2萬手,現報11.65元,暫成交5.3億元,最新總市值54億元。經緯輝開本週一(20日)晚間公佈公司擬使用自有資金對諾思(天津)微系統有限責任公司進行投資。諾思主要從事射頻前端薄膜體聲波濾波芯片及模塊的設計、研發、生產和銷售。諾思是中國首家射頻前端薄膜體聲波濾波芯片生產企業,技術水平世界領先,打破了歐美國家的技術壟斷,填補了國內射頻前端薄膜體聲波射頻芯片領域的空白,具有廣闊的市場前景。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.